Stamulumab

Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research[1][2].

Product Specifications

CAS Number

[705287-60-1]

Product Name Alternative

MYO-029

UNSPSC

12352203

Target

TGF-β Receptor

Type

Inhibitory Antibodies

Related Pathways

TGF-beta/Smad

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/stamulumab.html

Purity

95.07

Solubility

H2O

Smiles

[Stamulumab]

Molecular Weight

(142.56 kDa)

References & Citations

[1]P Singh, et al. Translational Pharmacokinetic/Pharmacodynamic Analysis of MYO-029 Antibody for Muscular Dystrophy. Clin Transl Sci. 2016 Dec;9 (6) :302-310.|[2]Kathryn R Wagner, et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008 May;63 (5) :561-71.